PRPH Quote, Financials, Valuation and Earnings

Insight Molecular Diagnostics, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of -4174.62%. ProPhase Labs, Inc.'s return on equity of -90.24% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.

ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 10099.56%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 31.09%. Given that ProPhase Labs, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Insight Molecular Diagnostics, Inc..

ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.183, suggesting its more volatile than the S&P 500 by 18.332%.

ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.

ProPhase Labs, Inc. quarterly revenues are $883K, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. ProPhase Labs, Inc.'s net income of -$6.8M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.93x versus 32.49x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of 14.51%. ProPhase Labs, Inc.'s return on equity of -90.24% beat Veracyte, Inc.'s return on equity of 2.52%.

ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 10099.56%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.10 which suggests that it could fall by -1.36%. Given that ProPhase Labs, Inc. has higher upside potential than Veracyte, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Veracyte, Inc..

ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.

ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.

ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. ProPhase Labs, Inc.'s net income of -$6.8M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 125.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.93x versus 7.67x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Exagen, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of -41.1%. ProPhase Labs, Inc.'s return on equity of -90.24% beat Exagen, Inc.'s return on equity of -140.03%.

ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 10099.56%. On the other hand Exagen, Inc. has an analysts' consensus of $15.43 which suggests that it could grow by 111.93%. Given that ProPhase Labs, Inc. has higher upside potential than Exagen, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Exagen, Inc..

ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison Exagen, Inc. has a beta of 1.801, suggesting its more volatile than the S&P 500 by 80.089%.

ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exagen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. Exagen, Inc. pays out -- of its earnings as a dividend.

ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than Exagen, Inc. quarterly revenues of $17.2M. ProPhase Labs, Inc.'s net income of -$6.8M is higher than Exagen, Inc.'s net income of -$7.1M. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while Exagen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.93x versus 2.32x for Exagen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of -774.52% compared to ProPhase Labs, Inc.'s net margin of -2.87%. ProPhase Labs, Inc.'s return on equity of -90.24% beat XWELL, Inc.'s return on equity of -224.93%.

ProPhase Labs, Inc. has a consensus price target of $13.80, signalling upside risk potential of 10099.56%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 775%. Given that ProPhase Labs, Inc. has higher upside potential than XWELL, Inc., analysts believe ProPhase Labs, Inc. is more attractive than XWELL, Inc..

ProPhase Labs, Inc. has a beta of -0.657, which suggesting that the stock is 165.684% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.697%.

ProPhase Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ProPhase Labs, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

ProPhase Labs, Inc. quarterly revenues are $883K, which are smaller than XWELL, Inc. quarterly revenues of $7.3M. ProPhase Labs, Inc.'s net income of -$6.8M is lower than XWELL, Inc.'s net income of -$211K. Notably, ProPhase Labs, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ProPhase Labs, Inc. is 0.93x versus 0.15x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.